Edgar Filing: RAY DEBANJAN - Form 4

DAX DEDANIAN

Form 4	INJAIN										
September 0	6, 2018										
FORM 4 UNITED STATES SE				CURITIES AND EXCHANGE COMMISSIC Washington D.C. 20549					OMB AF OMB Number:	APPROVAL 3235-0287	
Check th if no long subject to Section 1 Form 4 c Form 5 obligatio may com See Instr 1(b).	Washington, D.C. 20549 F CHANGES IN BENEFICIAL OWNERSHIP O SECURITIES Section 16(a) of the Securities Exchange Act of 1934 Public Utility Holding Company Act of 1935 or Sect of the Investment Company Act of 1940						Expires: January 31, 2005 Estimated average burden hours per response 0.5				
(Print or Type]	Responses)										
1. Name and Address of Reporting Person <u>*</u> RAY DEBANJAN			2. Issuer Name and Ticker or Trading Symbol CytomX Therapeutics, Inc. [CTMX]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(M				3. Date of Earliest Transaction Month/Day/Year) 09/04/2018				Director 10% Owner X Officer (give title Other (specify below) below) Chief Financial Officer			
				nendment, Date Original fonth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
FRANCISC	CO, CA 94080							reison			
(City)	(State)	(Zip)	Tab	le I - Non-D	Derivative	Secur	ities Acqu	uired, Disposed of	, or Beneficiall	y Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, any (Month/Day/Year)		n Date, if	Code (Instr. 3, 4 and 5)				5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	09/04/2018			Code V M(1)	Amount 3,000	or (D) A	Price \$ 1.4489	(Instr. 3 and 4) 8,928	D		
Common Stock	09/04/2018			S <u>(1)</u>	3,000	D	\$ 22.39	5,928	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: RAY DEBANJAN - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number orof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. l De Sec (In
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 1.4489	09/04/2018		M <u>(1)</u>	3,000	<u>(2)</u>	02/27/2024	Common Stock	3,000	

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
RAY DEBANJAN C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., SUITE 400 SOUTH SAN FRANCISCO, CA 94080			Chief Financial Officer			
Signatures						

/s/ Debanjan 09/05/2018 Ray Date **Signature of

Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- (2) 100% of the shares subject to the option are fully vested and exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.